Tenax Therapeutics (TENX) Stock Price, News & Analysis

Company Overview

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Key Stats

• Today's Range: $5.56 to $5.79
• 50-Day Range: $5.10 to $6.57
• 52-Week Range: $2.77 to $7.89
• Volume: 3,954 shs
• Average Volume: 160,366 shs
• Market Capitalization: $23.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Tenax Therapeutics Stock Analysis - MarketRank™

Tenax Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 643rd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tenax Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenax Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenax Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenax Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.26% of the float of Tenax Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenax Therapeutics has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Tenax Therapeutics has recently decreased by 7.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenax Therapeutics does not currently pay a dividend.

Dividend Growth

Tenax Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.26% of the float of Tenax Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenax Therapeutics has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Tenax Therapeutics has recently decreased by 7.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.47

News Sentiment

Tenax Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Tenax Therapeutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for TENX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Tenax Therapeutics is held by insiders.

Percentage Held by Institutions

Only 1.67% of the stock of Tenax Therapeutics is held by institutions.

TENX Stock Analysis - Frequently Asked Questions

How have TENX shares performed this year?

Tenax Therapeutics' stock was trading at $6.19 at the start of the year. Since then, TENX stock has decreased by 10.0% and is now trading at $5.57.
View the best growth stocks for 2025 here.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its earnings results on Tuesday, March, 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.34.

When did Tenax Therapeutics' stock split?

Shares of Tenax Therapeutics reverse split before market open on Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 3/25/2025
• Today: 5/10/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TENX
• CIK: 34956
• Web: www.tenaxthera.com
• Phone: 919-855-2100
• Fax: 919-855-2133
• Employees: 9
• Year Founded: 1967

Price Target and Rating

• Average Stock Price Target: $18.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +223.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,710,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.00%
• Return on Assets: -42.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 38.95
• Quick Ratio: 38.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $27.15 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 4,148,000
• Free Float: 3,283,000
• Market Cap: $23.10 million
• Optionable: Not Optionable
• Beta: 1.92